- Home
- ARMP vs AVX Comparison
ARMP vs AVX Comparison
Compare ARMP & AVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARMP | AVX |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.7M | 119.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ARMP | AVX |
|---|---|---|
| Price | $5.91 | $1.54 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 52.8K | ★ 167.3K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,054,000.00 | $1,319,011.00 |
| Revenue This Year | $4.48 | $530,767.50 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 8001.54 |
| 52 Week Low | $0.90 | $1.12 |
| 52 Week High | $16.34 | $25.38 |
Technical Indicators
Market Signals| Indicator | ARMP | AVX |
|---|---|---|
| Relative Strength Index (RSI) | 47.48 | N/A |
| Support Level | $5.66 | N/A |
| Resistance Level | $6.72 | N/A |
| Average True Range (ATR) | 0.72 | 0.00 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 16.59 | 0.00 |
Price Performance
Historical ComparisonAbout ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About AVX Avax One Technology Ltd.
AVAX One Technology Ltd is a public company offering investors regulated access to the Avalanche (AVAX) ecosystem. By integrating the reliability of U.S. capital markets with the growth potential of decentralized finance, it seeks to create a bridge between traditional and digital finance. The company focuses on building a digital-asset treasury, fostering innovation, and investing in decentralized financial technologies that benefit from the Avalanche network.